Loyal investors in Faron Pharmaceuticals (LSE: FARN) hoping that there might be a straight forward explanation for the failure of the Phase III INTEREST trial of traumakine might be disappointed in a statement issued by the company on Friday.
Shares in the Finland-based biopharma company crashed by almost 90% on Tuesday with the news that the candidate had failed to meet the primary endpoint in a trial of patients with acute respiratory distress syndrome, a severe orphan disease with a high mortality rate.
Traumakine did not bring patients an increased number of ventilator-free survival days or a reduced mortality rate when compared to placebo.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze